On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis
Open Access
- 24 January 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (1) , e161
Abstract
Clinical improvement in inflammatory bowel disease (IBD) treated with methotrexate and 6-mercaptopurine (6-MP) is associated with a decrease in pro-inflammatory cytokines. This has been presumed to indicate the mechanism of action of methotrexate and 6-MP. Although controversial, there are increasingly compelling data that Mycobacterium avium subspecies paratuberculosis (MAP) may be an etiological agent in some or all of IBD. We hypothesized that the clinical efficacy of methotrexate and 6-MP in IBD may be to simply inhibit the growth of MAP. The effect on MAP growth kinetics by methotrexate and 6-MP were evaluated in cell culture of two strains each of MAP and M. avium using a radiometric (14CO2 BACTEC®) detection system that quantifies mycobacterial growth as arbitrary “growth index units” (GI). Efficacy data are presented as “percent decrease in cumulative GI” (% −ΔcGI). The positive control antibiotic (clarithromycin) has ≥85% −ΔcGI at a concentration of 0.5 µg/ml. The negative control (ampicillin) has minimal inhibition at 64 µg/ml. MAP ATCC 19698 shows ≥80% −ΔcGI for both agents by 4 µg/ml. With the other three isolates, although more effective than ampicillin, 6-MP is consistently less effective than methotrexate. We show that methotrexate and 6-MP inhibit MAP growth in vitro. Each of the four isolates manifests different % −ΔcGI. These data are compatible with the hypothesis that the clinical improvement in patients with IBD treated with methotrexate and 6-MP could be due to treating a MAP infection. The decrease in pro-inflammatory cytokines, thought to be the primary mechanism of action, may simply be a normal, secondary, physiological response. We conclude that henceforth, in clinical studies that evaluate the effect of anti-MAP agents in IBD, the use of methotrexate and 6-MP should be excluded from any control groups.Keywords
This publication has 21 references indexed in Scilit:
- Phenotype at diagnosis predicts recurrence rates in Crohn’s diseaseGut, 2005
- High prevalence of Mycobacterium avium subspecies paratuberculosis IS 900 DNA in gut tissues from individuals with Crohn’s diseaseGut, 2005
- Mesalamine promotes intestinal epithelial wound healingin vitrothrough a TGF-beta-independent mechanismScandinavian Journal of Gastroenterology, 2005
- Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's diseaseThe Lancet, 2004
- On the etiology of Crohn disease.Proceedings of the National Academy of Sciences, 1996
- Methotrexate for the Treatment of Crohn's DiseaseNew England Journal of Medicine, 1995
- Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicityDigestive Diseases and Sciences, 1994
- Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutolAntimicrobial Agents and Chemotherapy, 1992
- IS901, a new member of a widespread class of atypical insertion sequences, is associated with pathogenicity in Mycobacterium aviumMolecular Microbiology, 1991
- Growth of Mycobacterium paratuberculosis in radiometric, middlebrook and egg-based mediaVeterinary Microbiology, 1990